FNY Investment Advisers LLC Invests $244,000 in Zoetis Inc. (NYSE:ZTS)

FNY Investment Advisers LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the fourth quarter, Holdings Channel reports. The institutional investor bought 1,499 shares of the company’s stock, valued at approximately $244,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Pensionfund Sabic increased its stake in Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after purchasing an additional 4,000 shares in the last quarter. PFW Advisors LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at about $1,764,000. JPMorgan Chase & Co. increased its position in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after buying an additional 279,092 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in Zoetis during the 3rd quarter worth approximately $11,684,000. Finally, B&L Asset Management LLC bought a new position in Zoetis in the third quarter worth approximately $563,000. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Finally, Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $211.89.

Zoetis Stock Down 1.2 %

ZTS opened at $164.31 on Wednesday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The firm has a market capitalization of $74.13 billion, a P/E ratio of 30.89, a PEG ratio of 2.91 and a beta of 0.89. The company’s 50-day moving average is $171.31 and its 200 day moving average is $180.16. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.36 EPS. Research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio is 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.